Athersys Reports Interim Analysis Results Of MASTERS-2 Clinical Study With MultiStem In Ischemic Stroke, Signs Memorandum Of Understanding For Global ARDS License With Healios; Includes $1.5M To $4.5M Near Term Payments Plus Up To $150M In Milestones
Portfolio Pulse from Benzinga Newsdesk
Athersys, Inc. (NASDAQ:ATHX) has reported interim analysis results of its MASTERS-2 clinical study with MultiStem in ischemic stroke, indicating that the current sample size of 300 patients is insufficient to achieve the primary endpoint. The company plans to conduct additional data analysis and pause enrollment of new patients. Athersys has also signed a Memorandum of Understanding (MOU) with HEALIOS K.K. for global ARDS license, which includes $1.5M to $4.5M near term payments and up to $150M in milestones. If Athersys is unable to secure a strategic transaction or adequate financing, it may have to file for bankruptcy protection.
October 10, 2023 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Athersys' MASTERS-2 study results indicate a need for larger sample size. The company has signed an MOU with Healios, which could provide near-term capital and potential milestone payments. However, the risk of bankruptcy looms if the company fails to secure adequate financing.
The interim results of the MASTERS-2 study indicate that the current sample size is insufficient, which could potentially delay the study and impact the company's stock negatively. The MOU with Healios could provide some financial relief, but the company's mention of potential bankruptcy indicates a precarious financial situation.
CONFIDENCE 90
IMPORTANCE 100
RELEVANCE 100